Sign In
Buy SLDB
$8.30
-0.0300 (-0.360%)
At Close: Jun 22, 2026
Solid Biosciences Reports Third Quarter 2020 Financial Results and Provides Business Update
07:00am, Thursday, 05'th Nov 2020
–IGNITE DMD clinical trial expected to resume dosing in the first quarter of 2021 –
Solid Biosciences to Host Third Quarter 2020 Financial Results and Business Update Call on November 5, 2020
07:30am, Tuesday, 03'rd Nov 2020
CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne),
